Last reviewed · How we verify
CHR-2797
At a glance
| Generic name | CHR-2797 |
|---|---|
| Also known as | Aminopeptidase inhibitor, Proposed INN: tosedostat |
| Sponsor | CTI BioPharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects (PHASE1)
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (PHASE1)
- Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE1, PHASE2)
- Study of Clinical Efficacy and Safety of Tosedostat in MDS (PHASE2)
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (PHASE2)
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (PHASE2)
- Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
- A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHR-2797 CI brief — competitive landscape report
- CHR-2797 updates RSS · CI watch RSS
- CTI BioPharma portfolio CI